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Killing of Microbes and Cancer 
by the immune System with 
Three Mammalian Pore-Forming 
Killer Proteins
Eckhard R. Podack† and George P. Munson*
Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, USA
Immunology is the science of biological warfare between the defenses of our immune 
systems and offensive pathogenic microbes and cancers. Over the course of his scien-
tific career, Eckhard R. Podack made several seminal discoveries that elucidated key 
aspects of this warfare at a molecular level. When Eckhard joined the complement lab-
oratory of Müller-Eberhard in 1974, he was fascinated by two questions: (1) what is the 
molecular mechanism by which complement kills invasive bacteria? and (2) which one 
of the complement components is the killer molecule? Eckhard’s quest to answer these 
questions would lead to the discovery C9 and later, two additional pore-forming killer 
molecules of the immune system. Here is a brief account of how he discovered poly-C9, 
the pore-forming protein of complement in blood and interstitial fluids: Perforin-1, 
expressed by natural killer cells and cytotoxic T lymphocytes; and Perforin-2 (MPEG1), 
expressed by all cell types examined to date. All the three killing systems are crucial for 
our survival and health.
Keywords: complement, C9, Perforin-1, Perforin-2, MPeG1, cytotoxic T cells, natural killer cells, pore-forming 
protein
iNTRODUCTiON
The immune system is faced with the difficult tasks of surveillance and elimination of pathogenic 
microbes and cancers. The elimination of the invaders – here defined broadly as cancers, viruses, 
extracellular, or intracellular bacteria – can be achieved by a physical process involving the insertion 
of clusters of pores on targeted membranes that perforate the bacterial envelope or damage the 
cytosolic membranes of infected or cancerous cells. These assaults disrupt the permeability barrier 
that is required for maintaining the life of all cells. By itself, barrier disruption by pore formation 
can be lethal if it is sufficiently extensive. Less extensive pore formation may nonetheless lead to the 
destruction of the targeted entity by facilitating the delivery of ancillary lethal agents to sensitive sites 
of the targeted cell or bacterium.
The evolution of three pore-forming proteins was probably driven by the need to assure destruc-
tion of invaders, regardless of the type of pathogen, or location of the invasion. Different  – but 
sometimes overlapping and perhaps complementary – strategies are required by the immune 
system to eliminate extracellular bacteria (complement and poly-C9), intracellular viruses and 
cancer cells (Perforin-1), and intra- and extracellular bacteria (Perforin-2). Through his interest in 
biological killing, Eckhard R. Podack discovered all three pore-forming proteins of the mammalian 
immune system and defined their critical importance in immune defense. Here is a brief account 
FiGURe 1 | Domain organization of C9, Perforin-1, and Perforin-2. All the three pore-forming proteins contain amino-terminal signal peptides (gray cylinders) 
and membrane attack complex perforin (MACPF) domains. Unlike the soluble proteins C9 and Perforin-1, Perforin-2 is a type I membrane protein with a membrane 
spanning alpha helix (black cylinder) near its carboxy terminus. The short cytosolic tail (wavy line) of Perforin-2 is ubiquitylated by a CRL in response to PAMPs such 
as LPS. Perforin-2 also contains a domain of unknown function (DUF) that is conserved among Perforin-2 orthologs. Domain architecture was retrieved from UniProt 
entries P02748, P14222, and Q2M385. Abbreviations: TSP1, thrombospondin type-1 repeat; LDL, low-density lipoprotein receptor class A repeat; EGF, epidermal 
growth factor-like domain; C2, calcium-dependent phospholipid-binding domain. This figure was adapted from McCormack et al. (1).
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of his hypotheses that resulted in the discovery of these critical 
immune effectors and their function in the context of other 
important developments in science.
The Molecular Mechanism of Pore 
Formation
The analogy to human warfare of immune destruction of patho-
genic invaders by pore-forming proteins is obvious. The most effec-
tive way of killing an enemy is by the bullet of a gun, creating a 
potentially lethal hole by physical forces. Machine gunning is even 
more effective by creating multiple holes in the target. By analogy, 
the three pore-forming proteins of the immune system, such as 
C9, Perforin-1, and Perforin-2, are the bullets creating direct and 
immediate physical damage by inserting clusters of pores or holes 
(machine gunning) of large inner diameter (10–16 nm) into the 
envelope of the targeted microbes or cells, respectively. The destruc-
tive bullets of the immune system, the pore-forming proteins, must 
be carefully targeted by use of specialized “guns” depending on 
the nature and location of the invader. The bullet of the immune 
system, such as the bullet of a gun, is blind as to its target and kills 
whatever it hits. Collateral damage has to be minimized.
As mentioned earlier, perforation of the cell membranes 
or bacterial envelopes is achieved by the formation of dense 
clusters of large pores of 10–16 nm inner diameter, assembled 
by a family of the three pore-forming proteins of the immune 
system. The three pore formers are complement component C9 
secreted into blood and interstitial fluid, Perforin-1 expressed 
in cytotoxic T cells and natural killer (NK) cells, and Perforin-2 
expressed by all phagocytic and all non-phagocytic cells exam-
ined to date. C9, Perforin-1, and Perforin-2 share the conserved 
membrane attack complex perforin (MACPF) domain, which 
functions in these proteins as a pore-forming killer domain 
(Figure  1) (1–3). These MACPF domains consist of 316–372 
amino acids and although they share low overall homology 
(<50%) they contain the signature motifs that define them as 
members of the MACPF family (see Prosite entries PS00279 and 
PDOC00251 at http://prosite.expasy.org).
Pore formation by the MACPF ensues through homopo-
lymerization of several monomers, which causes their MACPF 
domains to refold during polymerization to a hollow cylinder 
of 16 nm in length and an internal diameter of 10 nm for C9, 
16 nm for Perforin-1, and 10 nm for Perforin-2 (4–14). Refolding 
of the MACPF domain during polymerization exposes hydro-
phobic sites that insert 5 nm deep into the hydrophobic interior 
of membranes or bacterial cell walls (4). Polymerization of the 
pore former is self-limiting by closure of the cylindrical complex 
that is anchored by its 5 nm long hydrophobic segment in the 
hydrophobic interior of the cell membrane or bacterial envelope, 
respectively. The inside of the cylinder is hydrophilic, creating 
a 10–16  nm wide, water-filled pore, reaching 5-nm deep into 
the bacterial membrane core or breaching the cell membrane. 
It is important to note that during immune attack large clusters 
of pores are formed on the target membrane (analogy machine 
gun) by all the three pore formers. The dense clusters disrupt 
large surface areas of the bacterial envelopes rendering them 
susceptible to secondary attack by ancillary agents, such as 
reactive oxygen and nitrogen species, lysozyme, and proteases. 
In the absence of Perforin-2, the ancillary effectors cannot kill 
pathogenic bacteria (14). Similarly, Perforin-1 pores are required 
for the penetration of granzymes to help kill virus-infected and 
cancer cells.
The Discovery of the Pore-Forming 
Protein of Complement: Poly-C9
While studying purified human C9, Eckhard unexpectedly 
observed that C9 lost its hemolytic activity – a measure of 
complement function – at concentrations greater than 1 mg/ml. 
He subsequently employed electron microscopy and analytical 
ultracentrifugation, among other techniques, to determine the 
reason for this unexpected property (4, 15). With the electron 
microscope, he observed structures (1) that were nearly identi-
cal to the images of the entire C5b–9 membrane attack complex 
(MAC) that had been previously reported (4, 16). Yet, Eckhard’s 
samples were comprised solely of C9. Thus, Eckhard correctly 
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deduced that the cylinder of the MAC C5b–9 must be composed 
primarily of polymerized C9.
Eckhard’s report, coauthored with Jurg Tschopp in 1981, 
of pore formation via polymerization and refolding of a 
single protein species (C9) was likely the first demonstration 
and molecular understanding of the molecular mechanism 
of pore formation (17). He had also found the answers to the 
two questions that had initially intrigued him when he joined 
Müller-Eberhard’s laboratory: what is the molecular mechanism 
by which complement kills invasive bacteria? and which one 
of the complement components is the killer molecule? For the 
former, he had shown that it was polymerization of C9, and for 
the latter, he identified C9 as the pore-forming killer molecule 
of complement (15, 17, 18).
At high concentrations, purified C9 in solution spontane-
ously polymerizes at 37°C or room temperature or very slowly 
at 4°C (4, 15). Polymerized C9 (poly-C9) sediments at 27S in 
the analytical ultracentrifuge, monomeric C9 at 4.5S. On SDS 
page, the apparent molecular weight increases from 70,000 Da 
for the C9 monomer to ~1,000,000  Da for poly-C9. Electron-
microscopic images reveal that poly-C9 assumes the shape of a 
100 Å-wide, 160 Å-long hollow cylinder that has a 5-nm long 
hydrophobic domain on one end that transverses lipid bilayers. 
Monomeric C9 is a globular, elliptic protein with axes length of 
~5 and 8  nm (4). The cylindrical structure of poly-C9 closely 
resembles the structure of the entire C5b–8–poly-C9 complex, 
the MAC. The C5b–8 subunits are arranged into a narrow rod 
shaped, heteromeric complex that contributes little to the overall 
structure of the MAC-cylinder, even though it is integrated into 
the poly-C9 complex (18). The important function of C5b–8 is to 
trigger C9 polymerization and direct its membrane attack to the 
proper target, the bacterial surface. Although C5b–8 generates 
small transmembrane channels in cells and lyses red blood cells, 
it is insufficient to kill and lyse bacteria that have a thick outer 
cell wall. For killing of bacteria, C9 polymerization is required, 
which allows lysozyme access to the proteoglycan layer and 
causes the collapse of bacteria, most likely through the digestion 
of proteoglycan (19). To avert collateral damage by complement, 
our own cells are protected by CD55, preventing C3 binding, 
and CD59 preventing C8 binding and C9 polymerization. In 
addition, blood contains the S-protein also known as vitronectin 
that binds the MAC in solution and prevents C9-polymerization 
to prevent bystander lysis of our cells (5, 6, 20). Acquired defi-
ciency of the complement protective proteins on our cells causes 
paroxysmal nocturnal hemoglobinuria (PNH), which is lethal if 
untreated (7–9).
insights and inspirations from the 
Discovery of Poly-C9
The bilayer structure of cell membranes was discovered after elec-
tron microscopy had been developed in the 1950s. In 1964, Borsos 
et  al. described electron microscopic “complement lesions” of 
about 100 Å diameter on the membranes of erythrocytes lysed by 
complement (10). Similar complement lesions were subsequently 
found also on cell walls of bacteria killed by complement (11). 
In 1972, Mayer proposed in a theoretical paper that membrane 
lesions represent rigid structures formed by C5, C6, C7, C8, and 
C9 of complement that look like donuts with a central hydrophilic 
hole (21). He also considered a donut endowed with enzymatic 
activity generating a leaky patch by enzymatically degrading 
membrane lipids or other components. The donut is a symmetri-
cal ring, and it remained unexplained how the five different pro-
tein molecules, such as C5, C6, C7, C8, and C9, may be arranged 
to form such a symmetrical structure. Tranum-Jensen et  al. in 
1978 isolated the C5b–9 complex from erythrocyte membranes 
and showed that (direct quote), “The classical complement ‘rings’ 
visualized on membranes after complement lysis represent such 
C5b–9 cylinders perpendicularly oriented on the membranes” 
(16). The images confirmed the prediction of Mayer in which the 
donut is composed of C5–9 and extended the analysis to show 
that the donut is a hollow cylinder with an annulus forming the 
donut on one end.
The identification of C5b, C6, C7, C8, and C9 within the cylin-
drical complex remained a vexing riddle, given the symmetry of a 
cylinder and the diversity of the proteins forming it. This question 
was finally resolved with the discovery that isolated and purified 
C9 spontaneously polymerizes to poly-C9, forming a cylindrical 
complex that has an almost identical appearance as the C5b–9 
MAC (4). C5b–8 forms a long rod-like structure attached to the 
bacterial membrane that triggers C9 to polymerize and form the 
C5b–8–poly-C9 cylinder (MAC) that is detected as complement 
lesion in the membrane. C5b–8 is integrated as a subunit into the 
polyC9 cylinder (22).
Pore Formation is Driven by  
Physico-Chemical Forces Not 
Requiring enzymatic Activity
The fact that isolated, purified C9 spontaneously polymerizes in 
solution to a cylindrical complex suggests that the driving force 
for refolding of C9 and exposure of its hydrophobic domain 
even in aqueous solution is driven by physical interaction of 
C9 monomers during polymerization. The chain reaction of 
polymerization is self-limiting through the formation of a hollow 
cylinder. Intermediate polymers (half rings, representing a half 
cylinder sectioned along its long axis) are detected by electron 
microscopy when C9 is limited or is obstructed by other mem-
brane components.
The C9-polymer is likely formed by the stepwise addition 
of C9 monomers that unfold and insert into lipid. Each added 
unfolding C9 monomer is hydrophobic on the outside allowing 
lipid binding and is hydrophilic on the luminal side, repelling 
lipid from the inner side of the forming cylinder. The hydrophilic 
domains thereby repel lipids, which will be replaced by water and 
its solutes. In this way, we suggest, a water-filled, 100 Å wide pore 
is inserted solely by physical forces literally pushing hydrophobic 
lipids away. This analysis generated the first molecular model 
of pore formation by a single protein in 1982 (15). Eckhard’s 
model has recently been confirmed and refined in more detail 
by crystallization of the MACPF domain and detailed molecular 
studies (13, 23–28). Most recently, cryo-electron microscopy has 
revealed the structure of soluble poly-C9 at a resolution of 8 Å 
(Figure 2) (29, 30). This latter structure is composed of 22 C9 
FiGURe 2 | Structure of poly-C9 at 8 Å resolution. Side, tilted, and top views of soluble poly-C9 obtained by cryo-EM. In this reconstruction, 22 C9 molecules 
polymerize to form a symmetrical structure with globular domains atop a membrane penetrating 88 stranded β-barrel with a diameter of 120 Å. Graphic 
representations were derived from PDB file 5FMW and rendered with NGL Viewer (27).
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monomers forming a pore of 120 Å, close to Eckhard’s original 
measurements. The poly-C9 pores are used by additional ancil-
lary antimicrobial agents to attack sensitive sites in the bacterial 
envelope. Only when C9 is added to the C5b–8 complex, can 
lysozyme cause the collapse of bacterium most likely by degrada-
tion of the proteoglycan layer that forms the “skeleton” of the 
bacterium (19).
It may not be too farfetched to compare the firing of poly-C9 
by C5b–8 with a bullet fired by a gun. Poly-C9 blows a large, by 
molecular standards, pore (hole) into membranes, just like bul-
lets make holes into targets by physical force. Bullets are fired by 
pulling the trigger of the gun, after the gun has been aimed at the 
target. Likewise, triggering C9 polymerization is accomplished 
by C5b–8, but it is the bullet C9 that hits the target. C5b–8 is 
assembled on the target bacterium by activated C3 that assumes 
the function of recognition and aiming. C9 is blind to the target 
it hits. It would kill our own cells just as well as bacteria, if our 
cells were not protected by the CD55 and CD59 proteins to block 
C3b activation and C9 polymerization, respectively. Acquired 
deficiency of these protective molecules causes PNH due to 
uncontrolled complement lysis of our cells (collateral damage) 
that can be lethal if untreated (7–9).
The Discovery of Perforin-1 in Natural 
Killer Cells and Cytotoxic T Lymphocytes
Natural killer cells kill cancer cells. Cytotoxic T lymphocytes 
(CTL) kill virus-infected cells and cancer cells after activation, 
clonal expansion, and differentiation of naive CD8+ T cells into 
CTL. The molecular mechanism of how NK cells or CTL kill their 
target cells was not known before 1983, and the T cell receptor 
was first cloned in 1984 (31). Many hypotheses suggested that 
secreted factors – lymphotoxin, TNF (cachectin), and NK cytol-
ytic factor (NKCF) – were mediating cytotoxic activity (32–34). 
Another hypothesis invoked a role for ATP in killing (35). Yet, 
another hypothesis considered that the firm attachment between 
CTL and target caused target cell membrane shearing resulted 
in death of the target (36, 37). Finally, a popular hypothesis sug-
gested that CTL can express complement proteins C5–C9 for use 
in killing of target cells.
Eckhard considered the hypothesis that killer lymphocytes 
may be endowed with a pore-forming killer protein similar to C9 
of complement, making pores that can be detected by negative 
staining electron microscopy at 50,000-fold or higher magnifica-
tion. In 1982, Eckhard initiated a collaboration with his friend 
Dr. Gunther Dennert at the Salk institute in La Jolla – who at the 
time was culturing and cloning NK cells – to determine whether 
or not NK cells use a pore-forming protein to kill their target cells. 
They subsequently found that mixing NK cells with tumor cells as 
targets and adding concanavalin A-induced killing of the tumor 
cells. Isolating membranes from the mixture and examining them 
by negative staining in the electron microscope revealed clusters 
of membrane pores similar to – but not identical to – poly-C9 of 
complement. NK cell-mediated pores have a diameter of 16 nm 
and project 12  nm above the membrane. The ultrastructure 
suggested a polymeric composition of about 14–16 protomers. 
Assuming 5-nm deep membrane insertion, the cylindrical or 
tubular complex thus had the dimensions of 16 nm length with an 
internal diameter of 16 nm. One end of the cylinder bears a 4- to 
5-nm long hydrophobic domain which is membrane inserted. 
The other end of the cylinder bears an annulus that resembles a 
donut when viewed from the top.
Based on the morphology of the polymers ultrastructure and 
lymphocytic expression, it was clear to Eckhard and Gunther 
that they had identified a new, previously unknown protein. 
In reference to its membrane perforating ability, they named 
the monomeric protein Perforin-1 and its cylindrical polymer, 
poly-Perforin-1. They submitted their findings to Nature and 
the reviewers suggested publication. The Senior Editor of Nature 
agreed with the condition that they remove the name Perforin-1 
and poly-Perforin-1. The editor insisted that the names were 
premature and unwarranted. Although Eckhard and Gunther did 
not necessarily agree with the editor, they reluctantly replaced 
Perforin-1 and poly-Perforin-1 with the descriptive terms 
“tubule” and “tubular structure” so as not to delay publication 
(12). Henkart and Dourmashkin had previously shown lesions 
on target cells killed by antibody-dependent cytotoxicity that 
were larger than those of complement (38). It is likely that these 
lesions were made by Peforin-1, called cytolysin by Henkart’s 
group, but the nature of the killer cell remained unclear. Thus, 
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Eckhard and Gunther’s Nature paper was the first to define the 
molecular killing mechanism used by a bona fide cloned lym-
phocyte (NK cell) (12). Today, the moniker “Perforin-1” is now 
officially and broadly accepted. However, its initial rejection by 
the editor of Nature has caused the foundational paper on the 
subject to be regularly overlooked, because it is not revealed by 
the search term “perforin.” Eckhard felt that this invisibility had 
adverse consequences for his career and his research team during 
those pivotal years. This experience shaped Eckhard’s discussions 
with reviewers and editors who initially challenged his use of 
“Perforin-2” – the third pore-forming protein discovered over 
the course of his career – rather than the official name of MPEG1.
The name Perforin-1 was accepted by the editor in Gunther 
and Eckhard’s second paper on the subject in the Journal of 
Experimental Medicine (39). This paper revealed that CTL used 
the exact same pore-forming mechanism for the killing of target 
cells as did NK cells. For many T cell immunologists, the claim 
that the sophisticated T cell should use the same primitive mecha-
nism, pore formation, for killing as do NK cells and complement 
seemed unlikely and was not accepted for the next decade (40).
Perforin-1 is Contained in Cytolytic 
Granules
Both Henkart’s and Eckhard’s groups set out to further define 
the molecular mechanism by which Perforin-1 is activated and 
kills target cells (41, 42). Henkart’s team used a rat large granular 
lymphocyte tumor cell line to isolate cytoplasmic granules. 
Eckhard’s team had noticed and commented on the proximity 
in electron micrographs of cytoplasmic granules of killer lym-
phocytes (NK and CTL) to the contact site (synapse) with the 
target cell (12). The images suggested the hypothesis that the 
granules may contain the killer protein Perforin-1. Eckhard’s 
group used the murine CTL line CTLL2 to purify cytoplasmic 
granules. This cell line had been established by Kendall Smith 
and was widely used to titrate interleukin-2 (IL-2) (43). At the 
time (1983), the cells required only IL-2 for growth without the 
need for TCR stimulation. Electron micrographs revealed that 
CTLL2 contained many large cytoplasmic granules. CTLL2 cells 
were therefore chosen to isolate and analyze granules and their 
potential cytolytic activity (44).
Granules from CTLL2 in the presence of calcium ions are 
highly lytic for all tumor cell lines tested. Lysis is complete within 
less than 30 min. Granules also lyse red blood cells within 5 min 
allowing for a rapid assay by hemolysis. Lysis is strictly Ca2+ and 
temperature dependent. There is no lysis in the absence of calcium 
ions or at 4°C. The finding that granules from CTLL2 could lyse 
all kinds of tumor targets and red cells, suggested that they are 
unspecific in regard to the type of target they lyse. The specificity 
of CTL-mediated target lysis therefore must come from the CTL 
containing the granules that are released after contact with the 
target via the T-cell receptor.
Thus, in analogy to the pore-forming protein C9, the bul-
lets fired by the CTL or NK cell, Perforin-1, are blind as to the 
nature of their target. The targeting is accomplished by the CTL 
receptor or by NK receptors. Upon contact with the target cell, 
the granules of the killer cells are moved via microtubules to the 
contact site and released (exocytosed) onto the target membrane. 
Exocytosis into the interstitial space brings the granules into a 
Ca2+-containing environment which induces Perforin-1 polym-
erization and insertion of clusters of poly-Perforin-1 pores in 
target cell membranes. The pores are used by granzymes A-M 
that are contained in the same granule, to enter the cell and help 
killing by enzymatic action on several substrates that lead to DNA 
degradation and cell death. A low number of pores allow cells to 
repair the membrane, but entry of granzymes through the pore 
prevents survival. Large clusters of poly-Perforin-1 pores kill the 
target cell without ancillary granzymes.
Cloning of Perforin-1 and Comparison to 
C9, identification of the Membrane Attack 
Complex Perforin Domain
In the early 1980s, molecular biology was a new field. Cloning 
and sequencing projects could easily take a year or more. Eckhard 
began a collaboration with the Zinkernagel/Hengartner labora-
tory in Zurich, Switzerland, to clone Perforrin-1. This group was 
cloning the T-cell receptor specific for the lymphocytic chorio-
meningitis virus (LCMV) using a lamda-gt-11 protein expression 
library. This bacteriophage was used to introduce cDNA into 
Escherichia coli and drive protein expression of the cloned DNA. 
This allowed screening of lysed bacterial colonies with antibodies 
for the protein of interest. Using an anti-Perforin-1 antiserum 
prepared in house (monoclonal antibodies were not yet available), 
the collaborators screened the phage library for Perforin-1. This 
strategy eventually led to the successful cloning and sequencing 
of both human and mouse Perforin-1 (45, 46). At the same time, 
a group from Japan published the sequence of mouse Perforin-1 
by using oligonucleotide screening based on partial N-terminal 
Edman degradation of the protein and reverse translation (47). 
Eckhard’s team had previously also cloned and sequenced C9 in 
collaboration with Fey and DiScipio (42, 48). Both the Japanese 
and Eckhard’s group noted a sequence (domain) that was similar 
between C9 and Perforin-1. This common domain was subse-
quently officially named the MACPF domain. The discovery 
that C9, a single protein, can form membrane pores created a 
new paradigm of pore formation. Today, over 500 prokaryotic 
and eukaryotic proteins with MACPF domains are known and 
may form pores by identical principles – a protein is triggered to 
polymerize, refold, insert, and create pores in membranes. The 
targets of the MACPF domain are very diverse as are the triggers 
for polymerization.
The Biological Function of Perforin-1
Despite the published sequence of Perforin-1, there remained 
considerable doubt among T-cell scientists about the biologi-
cal importance of Perforin-1 in vivo. To address these doubts, 
Eckhard decided to knockout the gene for Perforin-1 in mice 
by homologous recombination, a technique first reported (49). 
Eckhard collaborated with Burki (Sandoz Pharma) and the 
Zinkernagel/Hengartner laboratory (Zurich) to publish the 
Perforin-1 knockout mouse in 1994 (50). Perforin-1 knock-
out mice are viable and fertile and have normal numbers of 
CD8+ T  cells and NK cells. However, these cells do not lyse 
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virus-infected cells, allogeneic fibroblasts, nor NK target cells 
in vitro. The Perforin-1 knockout mice also fail to clear LCMV 
in vivo, and they eliminate tumor cells with reduced efficiency 
(51). Perforin-1 is therefore a key effector molecule for T-cell- 
and NK cell-mediated cytolysis of virus-infected and cancer 
cells. For Eckhard, the observation that Perforin-1 in CD8+ CTL 
and NK cells may be involved in killing tumor cells was also 
personally important. As a physician, he had a particular interest 
harnessing the power of the immune system to defeat cancer and 
Perforin-1 in NK cells and CD8+ CTL seemed to offer a path 
forward (52).
The Nature publication finally convinced the scientific com-
munity of the biological importance of Perforin-1, the second 
pore-forming protein of the mammalian immune system to be 
described (50). In 1999, the first human Perforin-1 deficiency was 
reported (53). The deficiency caused familial hemophagocytic 
lymphohistiocytosis (FHL), a rare and rapidly fatal autosomal 
recessive immune disorder characterized by uncontrolled activa-
tion of T cells and macrophages, as well as overproduction of 
inflammatory cytokines. This latter report validated the biologi-
cal importance of Perforin-1 in humans.
The Discovery of Perforin-2
The common MACPF domain of C9 and Perforin-1 inspired 
Eckhard to Blast-search the NCBI database frequently with 
the consensus sequence of the MACPF domains of both pore-
forming proteins. Possibly, additional MACPF-containing 
proteins could be found that are not complement proteins or 
Perforin-1. Success came when expressed sequence tags (ESTs), 
a method pioneered by Craig Venter at the NIH, were made pub-
licly available by the NCBI in 1995. Within the ESTs, Eckhard 
found several that contained a novel MACPF domain. Following 
the source of the MACPF ESTs, it seemed that the new MACPF 
protein is expressed in macrophages. Eckhard assembled the 
complete open reading frame of the novel protein from several 
overlapping ESTs. The predicted protein appeared to be a 78-kDa 
protein containing a signal peptide followed by a MACPF 
domain at its amino terminus (Figure 1). It also contains a pre-
dicted transmembrane domain near its carboxy terminus. The 
predicted protein therefore was a type 1 membrane protein with 
a short cytosolic domain. This latter feature distinguished the 
new MACPF protein from the secreted polypeptides Perforin-1 
and C9 (Figure 1).
Concurrent with Eckhard’s discovery of a new MACPF encod-
ing gene in ESTs a manuscript was published in Blood describing 
a gene that is expressed during the differentiation of monocytes to 
macrophages. This novel gene was named macrophage-expressed 
gene 1 (Mpeg1) (54). The Mpeg1 encoded protein described 
by Spilsbury et  al. was largely identical to Eckhard’s MACPF 
protein, with the exception that Spilsbury’s predicted protein 
(GenBank accession AAA73957) lacked the transmembrane and 
cytosolic domains of Eckhard’s. This omission is most likely the 
result of a sequencing error as the domains are present in other 
GenBank records, for example, accession AAI12231 (human), 
XP_009184227 (baboon), XP_508450 (chimpanzee), Q2M385 
(mouse), and NP_001292389 (rat). Because the MACPF domain 
precedes the apparent sequencing error, Spilsbury et  al. were 
able to note that the product of the Mpeg1 gene shares distant 
ancestry to Perforin-1, the lytic protein found in CTL and NK 
cells (54). Surprisingly, to the best of our knowledge, the authors 
did not publish follow-up studies with their novel gene.
Perforin-2 and Pore Formation
Given the absence of functional analyses of this novel gene, 
Eckhard’s first objective was to determine if it was a pore-forming 
protein. To accomplish this, Eckhard’s group transfected various 
cell lines with plasmids expressing MPEG1–GFP fusion proteins 
and transfected various cell lines with the construct looking for 
GFP fluorescence. However, GFP+ cells would invariably die 
suggesting that the fusion protein was cytotoxic. Finally, after a 
year of experimenting, they found that HEK-293 cells were able 
to tolerate the fusion protein and survive. With the necessary 
cell line and reagents in place, the group was able to use electron 
microscopy to image pore-like structures in the membranes of 
transfected cells and in the membranes of bacteria exposed to 
cells expressing MPEG1 (14). Moreover, Eckhard and collabora-
tors found ample evidence that the pore-forming protein was 
a killer, bactericidal protein (1, 14, 55, 56). These observations 
supported Eckhard’s hypothesis that MPEG1 kills its targets by 
forming clusters of pores on target membranes, similar to C9 
and Perforin-1. The analogy to Perforin-1 also led Eckhard to 
advocate for the renaming MPEG1 to Perforin-2 because he felt 
that the latter moniker was more descriptive of its function than 
the former.
Macrophages phagocytose bacteria, especially when opsonized 
by complement, and kill bacteria intracellularly. The killing 
mechanism had been well established by 1995. According to the 
dogma at the time – also taught in textbooks – phagocytosed 
bacteria are killed by reactive oxygen and nitrogen species, by 
acidification, and lysosomal enzymes after fusion with the lyso-
some. According to this model, the killing of intracellular bacteria 
in macrophages does not require a pore-forming protein such as 
Perforin-2. This led Eckhard and his collaborators at the University 
of Miami to ask the following question – If macrophages already 
have perfectly good killing mechanisms why do they express 
Perforin-2? The answer was surprising and apparently paradigm 
shifting. The researchers found that macrophages are unable to 
kill phagocytosed bacteria (methicillin resistant Staphylococcus 
aureus, Salmonella typhimurium, Enteropathogenic E. coli, 
Mycobacterium smegmatis, Mycobacterium tuberculosis, Yersinia 
pseudotuberculosis, Chlamydia trachomatis, and other species) 
when Perforin-2 is knocked down by siRNA. Instead, the bacteria 
survive and replicate intracellularly (1, 14, 56). Moreover, killing 
was restored by transfection of Perforin-2 expression plasmids 
lacking the siRNA targeting regions (1, 14).
Further studies revealed that interferons induce the expression 
of Perforin-2 in fibroblasts, thus endowing them with the ability 
to kill invasive, intracellular pathogens (56). Interferon inducible 
or constitutive expression of Perforin-2 has been observed in 
all cell types analyzed to date (n ≥  70) (14). This raises the 
possibility that Perforin-2 is used by every cell in our bodies 
to kill pathogenic bacteria. Moreover, killing is not limited to 
intracellular compartments as we have shown that Perforin-2 
can also kill extracellular bacteria attached to the cytosolic 
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membrane (1). Eckhard also hypothesized that Perforin-2 may 
also protect against enveloped and/or endocytosed viruses. 
This hypothesis is currently under investigation by Eckhard’s 
collaborators at the University of Miami. Regardless of the 
outcome of this latter hypothesis, several studies by Eckhard and 
his collaborators have demonstrated that Perforin-2 is pivotal 
for the control and destruction of both intra- and extracellular 
bacteria (1, 14, 55–57).
The essential Role of Perforin-2 In Vivo
With several in  vitro studies confirming Eckhard’s hypothesis 
that Perforin-2 was a pore-forming bactericidal protein, he 
invested resources into the generation of Perforin-2 knockout 
mice. Perforin-2−/− mice are born healthy and do not require 
gnotobiotic conditions. Rather, they are colonized by commen-
sal microorganisms without ill effects and develop normally 
under pathogen-free conditions. Thus, Perforin-2 is neither 
required for development nor for the control of commensals. 
However, Eckhard and his colleagues found that Perforin-2 
knockout mice are highly susceptible to pathogenic bacteria 
even at low infectious doses. For example, Perforin-2−/− mice 
suffer progressive weight loss and perish 15–20  days after 
orogastric inoculation of just 105  CFU of Salmonella enterica 
serovar typhimurium (14). In contrast, wild-type mice suffered 
only transient weight loss and the majority of animals survived. 
Perforin-2 heterozygotes displayed a gene dosage effect with 
more severe weight loss and lower survival rates than wild-type 
littermates but not as severe as Perforin-2 knockout mice (14). In 
addition, Perforin-2 deficiency correlated with greater pathogen 
dissemination and higher bacterial loads in the blood, spleen, 
liver, and other organs. Similar patterns were observed after 
orogastric inoculation of Y. pseudotuberculosis or epicutaneous 
challenge with MRSA (1, 14). Thus, several in vivo and in vitro 
studies by Eckhard and his collaborators have now shown that 
Perforin-2 is a pore-forming protein and potent bactericidal 
molecule charged with limiting the proliferation and spread of 
infectious microbes (1, 14, 55–57).
Activation of Perforin-2 and  
Anti-Perforin-2 effectors
Perforin-2 is found in vesicles that stain with markers for plasma 
membrane, early endosomes, endoplasmic reticulum, Golgi, 
and the post-Golgi network (14). As a type I transmembrane 
protein, the orientation of Perforin-2 would place its MACPF 
domain in the lumen of intracellular compartments or the 
extracellular space if in the plasma membrane. In the absence 
of a pathogen-associated molecular pattern (PAMP), the overall 
cellular distribution of Perforin-2 is diffuse and perinuclear as 
determined by confocal microscopy of host cells transfected with 
Perforin-2–RFP expression plasmids (1). However, LPS – and 
presumably other PAMPs – or live bacteria trigger the ubiquity-
lation of Perforin-2’s cytosolic tail by a cullin-RING E3 ubiquitin 
ligase (CRL) followed by a rapid redistribution of Perforin-2 
into distinct punctate bodies (1). Mutagenesis of conserved 
lysine residues in the cytosolic tail of Perforin-2 abolishes its 
redistribution and Perforin-2-dependent killing (1). Thus, our 
observations suggest a model wherein ubiquitylation triggers the 
translocation of Perforin-2 laden vesicles to phagosomes and/
or the plasma membrane. Subsequent membrane fusion delivers 
the MACPF domain to the lumen of phagosomes or extracel-
lular space whereupon it polymerizes to perforate the envelope 
of phagocytosed bacteria or extracellular bacteria at the plasma 
membrane.
The importance of Perforin-2 to host defense is further sup-
ported by its conservation throughout evolution and its broad 
distribution across the animal kingdom from invertebrates 
to vertebrates (2, 3, 58, 59). However, if Perforin-2 is a potent 
and effective pore-forming protein, why do infectious diseases 
exist? The long evolutionary history of Perforin-2 suggests that 
pathogens have had ample time to evolve mechanisms to sup-
press or evade its bactericidal activity. We have recently validated 
this prediction by showing that enteropathogenic E. coli and 
Y. pseudotuberculosis inhibit Perforin-2-dependent killing by 
blocking its intracellular trafficking (1). This is accomplished by 
the bacterial effector protein Cif which is injected into the cytosol 
of host cells by the bacteria whereupon it proceeds to deamidate 
NEDD8 (60–62). NEDD8 is a member of the ubiquitin family of 
proteins and neddylation is essential for CRL-dependent ubiq-
uitylation of CRL substrate proteins (63, 64). Thus, Cif blocks 
Perforin-2-dependent killing by inhibiting its ubiquitylation 
through deamidation of NEDD8 (1). Although only a few spe-
cies of pathogenic bacteria express Cif, we suspect that evolution 
may have endowed most bacterial pathogens with the ability 
to inhibit or resist the bactericidal activity of Perforin-2. The 
identification of drugs that restore and/or increase Perforin-2 
activity may overcome these anti-Perforin-2 effectors and allow 
our own bodies to successfully combat the invaders. These new 
approaches may also provide a solution to the threat of wide-
spread antibiotic resistance.
SUMMARY AND CONCLUSiON
Over the course of his scientific career, Eckhard Podack dis-
covered and characterized three pore-forming proteins that are 
essential to protect our lives from bacteria, viruses, and cancer.
Complement and poly-C9 kill extracellular pathogens in 
blood and interstitial fluid. Although C9 deficiency is not lethal, 
it is associated with increased risk of chronic, recurring infection 
with Neisseria meningitides and Neisseria gonorrhea (65, 66). This 
suggests that Neisseria have mechanisms to block Perforin-2, 
but not poly-C9, which can kill them. Most other extracellular 
pathogens are detected by complement by one of its three activa-
tion pathways as well as additional proteins such as C-reactive 
protein (CRP). Complement activation-specific antibody and 
C3b deposition leads to opsonization and avid phagocytosis with 
subsequent intracellular killing, presumably by Perforin-2.
Peforin-1 kills virus-infected cells and cancer cells. Human 
Perforin-1 deficiency causes familial hemophagocytic lympho-
histiocytosis, which is lethal if not treated. It also protects us 
from cancer. All solid tumors have a mechanism to suppress 
CD8+ CTL production or action, thereby neutralizing Perforin-1 
activity. It is possible that methods overcoming cancer-induced 
neutralization of Perforin-1 through suppression of CD8+ CTL 
induction or activity, in combination with tumor-specific cancer 
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vaccines that generate CD8+ CTL, will allow remission or even 
cure of cancer.
Perforin-2 kills both intra- and extracellular bacteria. Unlike 
poly-C9 which is restricted to pore formation in the outer 
membrane of Gram-negative bacteria, Perforin-2 is a broad-
spectrum killer of Gram-positive, Gram-negative, and acid-fast 
pathogenic bacteria, including those that are antibiotic resistant. 
Its transmembrane domain further differentiates Perforin-2 from 
the other two pore-forming proteins of the immune system; 
however, it remains to be determined if cleavage from the 
membrane precedes polymerization and pore formation. Based 
on our observations with Perforin-2 knockout mice which are 
hypersusceptible to even low doses of bacterial pathogens, it 
is likely that individuals with complete Perforin-2 deficiency 
succumb to infectious disease early in childhood. This would 
have been especially true prior to the widespread availability of 
antibiotics. Individuals with Perforin-2 haplo-insufficiency may 
reach maturity but are likely to suffer higher rates of chronic 
and recurring infectious disease than the general population. 
Eckhard initiated a collaboration with Dr. Holland (NIH) to test 
this latter hypothesis and the analysis is ongoing.
The three pore-forming proteins of the human immune 
system therefore are essentially life-saving proteins protecting 
us from microbial invasion and providing surveillance against 
cancer formation.
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